Abstract:
Objectives: The current study aimed to investigate the potentiality of three lncRNAs
“Plasmacytoma variant translocation 1(lnc-PVT1), Taurine upregulated gene type 1(lnc-
TUG1) and Maternally expressed gene 3 (lnc-MEG-3)”, to predict Cisplatin resistance in
ovarian cancer (OC), in addition, to access their prognostic significance.
Methods: The expression level of lncRNAs were measured in 100 formalin-fixed paraffin-
embedded tissue (FFET) samples of OC patients who were treated by Cisplatin-based
chemotherapy using qPCR.Results: The results showed that lnc_PVT1 was significantly higher by 2.3 folds in Cisplatin
resistant tissues, while, lnc-TUG1 and lnc-MEG3 were downregulated by 1.2 and 3 folds,
respectively. In addition, the three lncRNAs exhibited high sensitivity and specificity in
predicting chemo-resistance and they were negatively associated with OS and progression-
free survival (p<0.001).
Conclusion: The lnc-PVT1, lnc-TUG1, and lnc-MEG3 transcriptome signatures could be
used for predicting resistance to Cisplatin in OC patients.
